A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020531 and Metabolites Following Oral Administration to Chinese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2018
At a glance
- Drugs RO 7020531 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 12 Sep 2018 Planned End Date changed from 12 Jan 2019 to 19 Jan 2019.
- 12 Sep 2018 Planned primary completion date changed from 12 Jan 2019 to 19 Jan 2019.
- 06 Jun 2018 Planned End Date changed from 13 Dec 2018 to 12 Jan 2019.